Fatty Liver Disease (NAFLD/NASH)
Metabolic liver disease driven by fat accumulation, inflammation, and fibrosis. MSC therapy reduces hepatic inflammation and supports liver regeneration.
Non-alcoholic fatty liver disease encompasses a spectrum from simple hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) — characterized by inflammation and hepatocyte injury — and progressive fibrosis leading to cirrhosis and hepatocellular carcinoma. NAFLD affects approximately 25% of the global population and is the fastest-growing indication for liver transplantation.
The pathogenesis involves insulin resistance, lipotoxicity, gut microbiome dysbiosis, and an amplifying hepatic inflammatory cascade mediated by activated Kupffer cells and stellate cells. No FDA-approved pharmacological therapy for NASH exists, and current management relies on lifestyle modification — which is effective but difficult to sustain.
MSC therapy targets the hepatic inflammatory and fibrotic cascade directly, offering a regenerative complement to lifestyle and metabolic optimization for NAFLD/NASH patients.
MSCs administered intravenously home to inflamed hepatic tissue, where they suppress Kupffer cell activation, reduce hepatic NF-κB signaling, and secrete HGF, IL-10, and TGF-β-counteracting factors that inhibit hepatic stellate cell activation and collagen deposition. This anti-fibrotic, anti-inflammatory paracrine effect has been demonstrated in multiple rodent NASH models.
Clinical series in NAFLD/NASH patients have documented reductions in AST, ALT, GGT, and liver stiffness (measured by fibroscan) following MSC infusion, alongside improvements in fasting insulin and BMI. Histological improvement — including reduction in NAFLD Activity Score and fibrosis stage — has been reported in several biopsied patients at 12 months.
True Regen coordinates fibroscan imaging, hepatic enzyme panels, insulin resistance assessment, and abdominal ultrasound before treatment and at follow-up intervals to track hepatic response.
- Reduced liver enzyme levels (AST, ALT, GGT)
- Decreased liver stiffness on fibroscan
- Improved insulin sensitivity and fasting glucose
- Reduction in hepatic fat content on imaging
- Slowed fibrosis progression
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.